Table 1 Clinicopathological characteristics of the overall study population

From: Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies

Characteristic

Overall study population (N = 512)

Age, median (range)

52 (25–97)

Age groups, no. (%)

 <50

238 (46%)

 >50

274 (54%)

Race, no. (%)

 White

423 (83%)

 Black/African American

34 (7%)

 Asian

25 (5%)

 Hispanic

14 (3%)

 Other

8 (2%)

 Not reported

8 (2%)

Stage at Dx, no. (%)

 

 Stage 1

145 (28%)

 Stage 2

247 (48%)

 Stage 3

74 (14%)

 Stage 4

43 (8%)

 Unknown

3 (1%)

ER status at Dx, no. (%)

 <1%

447 (87%)

 1–10%

65 (13%)

HER2 in 1st eligible Bx, no. (%)

 

 HER2-low

305 (60%)

 HER2-0

207 (40%)

NA therapy, no. (%)

 

 Yes

278 (54%)

 No

238 (45%)

 unknown

4 (1%)

No. of Bxs, no. (%)

 

 1

196 (38%)

 2

231 (45%)

 3

48 (9%)

 4

29 (6%)

 >5

8 (1%)

  1. Dx diagnosis, ER estrogen receptor, NA neoadjuvant.
Back to article page